Benjamin Caulier
- Postdoc; PhD, Msc
- +47 22 78 23 19
Scientia fellow II/Kreftforeningen
Education:
2014-2017: PhD in Biotechnology, Development of a non-integrative (protein vector) for the generation of clinical-grade induced pluripotent stem cells, Univ. Grenoble Alpes, TIMC-IMAG CNRS 5525, French Blood Bank, Grenoble, France
2015-2016: Label Research: Business, Industry & Innovation, Univ. Grenoble Alpes, Grenoble, France
2011-2013: Master degree in Molecular & Cell Biology, Specialty: Immunology, Microbiology & Infectiology, University Joseph Fourier, Grenoble, France
2010-2011: Bachelor degree in Engineering Sciences & Technology, Specialty: Risk Management, Quality Assurance & Environment, IRIAF, Niort, France
2008-2010: Undergraduate in Biology (DUT), Specialty: Environment
Research interests/projects:
Cancer immunotherapy, novel cellular strategies (development of CARs, TCR redirected cells), biotechnological engineering, induced pluripotent stem cells-based modeling
Work experience:
2020-Present: Postdoc, Development of CAR therapy, Department of Cellular Therapy, OUS-Radiumhospitalet, Oslo, Norway
2017-2019: Postdoc, Development of a therapeutic type-3 adenoviral-like particle (dodecamer) for the treatment of acute myeloid leukemia. Departments of Cellular Hematology & Pediatric Oncology, Grenoble Alpes Hospital, Institute for Advanced Biosciences, TIMC-IMAG, Univ. Grenoble Alpes, Grenoble, France
2014-2017: PhD student, Development of a non-integrative (protein vector) for the generation of clinical-grade induced pluripotent stem cells. TIMC-IMAG CNRS 5525, Team Experimental Recombinant Therapy, French Blood Bank, Univ. Grenoble Alpes, Grenoble, France
2012-2013: Intern, Induction of patient-specific cytotoxic T lymphocytes against non-small cell lung cancer (NSCLC) with a therapeutic allogeneic plasmacytoid dendritic cell line (vaccine). Institute for Advanced Biosciences INSERM U1209, Team Immunobiology & Cancer Immunotherapy, French Blood Bank, Univ. Grenoble Alpes, Grenoble.
2011-2012: Intern, Induction of cytotoxic T lymphocytes against viruses & melanoma cancer with a therapeutic allogeneic plasmacytoid dendritic cell line (vaccine). Institute for Advanced Biosciences INSERM U1209, Team Immunobiology & Cancer Immunotherapy, French Blood Bank, Univ. Grenoble Alpes, Grenoble.
Publications 2023
Efficient chimeric antigen receptor (CAR) targeting of a central epitope of CD22
J Biol Chem, 104883 (in press)
DOI 10.1016/j.jbc.2023.104883, PubMed 37269947
A New Plasmacytoid Dendritic Cell-Based Vaccine in Combination with Anti-PD-1 Expands the Tumor-Specific CD8+ T Cells of Lung Cancer Patients
Int J Mol Sci, 24 (3)
DOI 10.3390/ijms24031897, PubMed 36768214
Publications 2022
Recombinant Transcription Factors (TFs) Fused to ZEBRA Minimal Transduction Domain (MD) for Modulation of mRNA Transcripts
Methods Mol Biol, 2383, 275-291
DOI 10.1007/978-1-0716-1752-6_19, PubMed 34766297
How CAR T Cells Breathe
Cells, 11 (9)
DOI 10.3390/cells11091454, PubMed 35563759
Publications 2021
Pharmacologic Control of CAR T Cells
Int J Mol Sci, 22 (9)
DOI 10.3390/ijms22094320, PubMed 33919245
Publications 2020
Evaluation of the human type 3 adenoviral dodecahedron as a vector to target acute myeloid leukemia
Mol Ther Methods Clin Dev, 20, 181-190
DOI 10.1016/j.omtm.2020.11.009, PubMed 33473357
Publications 2017
Targeted release of transcription factors for human cell reprogramming by ZEBRA cell-penetrating peptide
Int J Pharm, 529 (1-2), 65-74
DOI 10.1016/j.ijpharm.2017.06.073, PubMed 28647433
Publications 2016
Targeted release of transcription factors for cell reprogramming by a natural micro-syringe
Int J Pharm, 513 (1-2), 678-687
DOI 10.1016/j.ijpharm.2016.09.081, PubMed 27697633